Collegium Pharmaceutical, Inc. Repayments of Convertible Debt
Collegium Pharmaceutical, Inc. (COLL) reported Repayments of Convertible Debt of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfConvertibleDebt · last filed 2026-02-26
- Collegium Pharmaceutical, Inc. repayments of convertible debt for the quarter ending 2023-12-31 was $0.00.
- Collegium Pharmaceutical, Inc. repayments of convertible debt for the quarter ending 2023-09-30 was $0.00.
- Collegium Pharmaceutical, Inc. repayments of convertible debt for the quarter ending 2023-06-30 was $0.00.
- Collegium Pharmaceutical, Inc. repayments of convertible debt for the quarter ending 2023-03-31 was $138.64M.
- Collegium Pharmaceutical, Inc. repayments of convertible debt for fiscal 2025 was $0.00.
- Collegium Pharmaceutical, Inc. repayments of convertible debt for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Collegium Pharmaceutical, Inc. repayments of convertible debt for fiscal 2023 was $138.64M.
| Period end | Repayments of Convertible Debt 3 month | Repayments of Convertible Debt 6 month | Repayments of Convertible Debt 9 month | Repayments of Convertible Debt 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $138.64M 10-K · filed 2026-02-26 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $138.64M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $138.64M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $138.64M 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |